Swedish drug firm AB Astra &lt;ASTS.ST>shares rose 48 crowns to 690 in the first two hours of tradingon the Stockholm Bourse, amid hopes its research intoanti-viral drugs may have promising results in the treatment ofAcquired Immune Deficiency Syndrome (AIDS).    Stockbrokers said the shares, which climbed amid heavyinstitutional buying, also rose in reaction to an optimisticassessment of future products in the firm's annual report whichwas released this week.    Brokers Enskilda Fondkommission said in a report this monththat Astra was a world leader in anti-viral drugs.    Although Enskilda said Astra had not made any breakthroughin developing a specific drug to treat the Acquired ImmuneDeficiency Syndrome it noted that investors were only nowdiscovering that the firm's approach in the area was promising.    "It is clear that Astra has a tradition in anti-viralresearch which should prove valuable in fighting this disease,"the report by Enskilda, the investment banking unit ofSkandinaviska Enskilda Banken &lt;SEBS.ST>, said.    Company officials could not be reached for comment on thecauses of today's share rise. REUTER&#3;